• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Long-term plasmapheresis therapy is effective and safe in children with chronic relapsing dysimmune polyneuropathy.

作者信息

Beydoun S R, Engel W K, Karofsky P, Schwartz M U

机构信息

USC Neuromuscular Center, University of Southern California School of Medicine, Los Angeles 90017.

出版信息

Rev Neurol (Paris). 1990;146(2):123-7.

PMID:2157270
Abstract

Since childhood, two persons, a boy age 12 and a girl age 24 years, with chronic relapsing dysschwannian neuropathy causing severe limb weakness have been maintained on frequent plasmapheresis for more than 8-1/2 and 9 years respectively. They are totally dependent on it. Onset of disease was at ages 2-1/2 and 9 years. Both patients had had major relapses, some requiring ventilatory support, despite continued maximally-tolerated pharmacologic antidysimmune treatment. Plasmapheresis was started in August 1980 and December 1979, respectively. The current schedule is a set of 3 in one week at eight-week intervals for patient 1 and twice every 7-10 days for patient 2. They have had more than 330 and more than 1,100 phereses respectively. Since beginning phereses, neither has had a major relapse, and both are functional in their daily life as students, although with slight and moderate residual weakness respectively. The dependence of these 2 patients on regular pheresis for the last 8-1/2 and 9 years proves its efficacy and safety in children. Long-term maintenance pheresis may be beneficial in patients with other forms of chronic dysimmune neuropathy.

摘要

相似文献

1
Long-term plasmapheresis therapy is effective and safe in children with chronic relapsing dysimmune polyneuropathy.
Rev Neurol (Paris). 1990;146(2):123-7.
2
A critical approach to therapeutic apheresis in the management of inflammatory dysimmune polyneuropathies.炎症性免疫性多神经病治疗中治疗性血液成分单采的关键方法。
Haematologia (Budap). 1985;18(1):33-43.
3
Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome.23例Lewis-Sumner综合征患者的随访研究及治疗反应
Brain. 2004 Sep;127(Pt 9):2010-7. doi: 10.1093/brain/awh222. Epub 2004 Aug 2.
4
[Steroid therapy and plasmapheresis in chronic inflammatory demyelinating polyradiculoneuropathy: a long-term follow-up study].
Rinsho Shinkeigaku. 1998 Mar;38(3):208-12.
5
[Immunotherapy of chronic inflammatory demyelinating polyneuropathy].[慢性炎症性脱髓鞘性多发性神经病的免疫治疗]
Fortschr Neurol Psychiatr. 2004 Dec;72(12):672-8. doi: 10.1055/s-2004-830039.
6
Intravenous immunoglobulin in chronic relapsing polyneuropathy.静脉注射免疫球蛋白治疗慢性复发性多发性神经病
N Z Med J. 1992 Feb 26;105(928):60-1.
7
[Pauci-symptomatic sensory polyneuropathy in Refsum's disease].[Refsum病中的少症状性感觉性多神经病]
Rev Neurol (Paris). 1996 Jun-Jul;152(6-7):469-72.
8
Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy".以“慢性感觉性脱髓鞘性多发性神经病”表现的病例中的迟发性运动受累
Muscle Nerve. 1995 Apr;18(4):440-4. doi: 10.1002/mus.880180411.
9
The dropped head syndrome with chronic inflammatory demyelinating polyneuropathy.慢性炎症性脱髓鞘性多发性神经病伴垂头综合征
Muscle Nerve. 1994 Jul;17(7):808-10. doi: 10.1002/mus.880170717.
10
Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients.慢性免疫性神经病。基于102例患者临床特征的一种分类。
J Neurol. 2003 Jun;250(6):714-24. doi: 10.1007/s00415-003-1068-2.

引用本文的文献

1
Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions.小儿慢性炎症性脱髓鞘性多发性神经病的治疗:挑战、争议与问题
Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):327-30. doi: 10.4103/0972-2327.160065.